All In Biotech

Drug Trial Radar · NCT06014762

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 16, 2024

Primary completion

Mar 2029

Study completion Mar 2041

Sponsor

Lead sponsor
Poseida Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Roche-Genentech
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Conditions

  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • High-grade B-cell Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Transformed Follicular Lymphoma (tFL)
  • Follicular Lymphoma Grade 3B
  • DLBCL
  • DLBCL - Diffuse Large B Cell Lymphoma
  • DLBCL Arising From Follicular Lymphoma
  • DLBCL, Diffused Large B Cell Lymphoma
  • DLBCL NOS

Interventions

  • P-CD19CD20-ALLO1Biological

    Single weight-based IV administration

  • RimiducidDrug

    Single weight-based IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the safety and MTD or RDE of P-CD19CD20-ALLO1 based on dose limiting toxicities (DLT)Time frame: Baseline through 28 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Cancer Center

    Loma Linda, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Advent Health Orlando

    Orlando, Florida

  • Indiana University

    Indianapolis, Indiana

  • Our Lady of the Lake Hospital

    Baton Rouge, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Wayne State - Karmanos Cancer Institute

    Detroit, Michigan

  • NYU Grossman School of Medicine

    New York, New York

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • University of Oklahoma, Health Sciences Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • Pennsylvania State University

    Hershey, Pennsylvania

  • Prisma Health - Upstate Cancer Institute

    Greenville, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor Scott & White Research Institute

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.